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Highlights 
 Patterns of drug injecting in UK gay and bisexual men are poorly understood 
 We examined correlates and subgroups of injecting drug use among GBM 
 HIV positive, middle-aged, or London-resident GBM most often reported injecting 
 GBM with sexual risk with multiple partners were most likely to report injecting 
 We found evidence for three types of injection drug use (chemsex, opiate, eclectic) 
 
 
 
Abstract 
Background: Evidence to understand which gay and bisexual men (GBM) inject drugs 
remains scant, especially in the UK. We describe correlates of last-year injecting in UK GBM, 
and characterise subgroups of GBM who inject drugs by types of drugs used. 
Methods: Using data from the 2014 Gay Men’s Sex Survey, an opportunistic internet-based 
survey conducted of GBM living in the UK, we examined via logistic regression correlates 
with any injecting of six drugs (amphetamine/speed, crystal methamphetamine, heroin, 
mephedrone, GHB/GBL, and ketamine) in the last year. We estimated latent class models to 
understand underlying subgroups of injecting drug use among GBM reporting injecting drug 
use in the last year. 
Results: Injecting was most common in GBM who were of middle age, who were HIV 
seropositive, and who lived in London, and was significantly associated with sexual risk with 
multiple partners in the last year, whether steady or non-steady. Most GBM who engaged in 
injecting either injected crystal methamphetamine, mephedrone or both (class 1, chemsex, 
88.6% of injectors), whereas a smaller group had a focus on opiates (class 2, opiate, 7.9%). A 
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small but identifiable subgroup (class 3, eclectic, 3.5%) engaged in injecting across the range 
of drugs examined. 
Conclusions: This is the first epidemiological analysis to describe subgroups of injecting, and 
to describe correlates of injecting drug use, in UK GBM. Implications for design of harm 
reduction services include a need to focus on injecting drug use beyond opiates, currently the 
focus of most harm reduction services. 
 
 
Keywords: injecting drug use; gay and bisexual men; latent class analysis; observational 
epidemiology 
 
1. Introduction 
 While drug use in gay and bisexual men (GBM) is consistently higher than in the 
general population (Lea et al., 2013; Melendez-Torres et al., 2016), injection drug use by gay 
and bisexual men (GBM) remains sparsely documented and poorly understood in the UK 
(Public Health England, 2016). This is despite increasing media attention from 2013 onwards 
(Kirby and Thornber-Dunwell, 2013; Shaw, 2017). Recent evidence from Australian GBM 
indicates a prevalence of drug injecting of 4.7% in the last six months, with lifetime prevalence 
of 10.6% (Bui et al., 2018), but epidemiological description of injecting drugs among UK GBM 
remains scant. While previous surveys document low levels of injection drug use among GBM 
in Europe (The EMIS Network, 2013), the emergence of ‘chemsex’, or the sexualised use of 
crystal methamphetamine, GHB, mephedrone and ketamine (Bourne et al., 2015a), has sparked 
concern about the current extent of injection drug use in this population. Injecting use of 
chemsex drugs may be a particularly salient feature of high-risk sexual practices, given the use 
of these drugs to enhance sexual performance and increase the number of partners in a coital 
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session (Bourne et al., 2015b), and we have previously described the relationship between 
chemsex drug use before sex and sexual risk at the level of the sexual encounter (Melendez-
Torres et al., 2017). Major cross-sectional surveys of drug use by GBM have not been able to 
recruit enough GBM who inject drugs for comparison (Sewell et al., 2017). Data from the 
Unlinked and Anonymous Monitoring survey of people who inject drugs compared GBM and 
non-GBM among men who inject drugs and found that GBM were more likely to have recently 
begun injecting and to engage in high-risk sexual practices; however, this survey was unable 
to describe patterns within GBM who inject drugs (Glass et al., 2017). Not all injection drug 
use may be related to sex, and different profiles of injection drug use may exist among GBM. 
We present an observational epidemiological study based on cross-sectional survey data from 
a large number of GBM across the UK, in which we describe demographic and socio-sexual 
correlates of drug injecting and characterise subgroups of GBM injectors by types of drugs 
used. 
2. Methods 
We used data from the Gay Men’s Sex Survey, a convenience sample survey of GBM 
living in the UK, and the longest-running community-based survey of GBM in the UK. GBM 
were recruited to an internet-based survey in late summer 2014 via dating websites, Facebook 
advertisements and geosocial networking apps. Because of the recruitment methods used, a 
response rate is not available. We included in this analysis GBM over the age of 16 who 
identified as gay, bisexual or with another non-heterosexual identity; that is, men who 
described being sexually attracted to men. 
2.1. Correlates with last-year injecting 
Because injecting was relatively rare in this sample, we examined any injecting in the 
last year of any of six drugs (amphetamine/speed, crystal methamphetamine, heroin, 
mephedrone, GHB/GBL, and ketamine) as our binary dependent variable. We tested a set of 
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bivariate logistic regression models, with independent variables including age group, region of 
residence, academic qualifications, full-time employment, HIV testing history, gay identity 
(defined as ‘gay’ or ‘bisexual and other non-heterosexual’), and number of steady and non-
steady partners and condom-unprotected anal intercourse (cUAI) in the last year. For both 
steady and non-steady partners, we constructed variables relating to both the quantity of 
partners and the sexual risk behaviours associated with each of those partnerships. This led to 
a four-category variable for non-steady partners: respondents reported one or more non-steady 
partners, but with no cUAI in any of those partnerships; respondents reported one non-steady 
partner with no cUAI in that partnership; respondents reported one non-steady partner with 
cUAI in that partnership; and respondents reported two or more non-steady partners with cUAI 
in two or more partnerships. Of note is that respondents could report both steady and non-
steady partners in the last year. We constructed a similar variable for steady partners. 
Independent variables were chosen on the basis of our prior work in understanding drug use 
patterns in GBM (Melendez-Torres et al., 2016), and account for both demographic 
characteristics and behavioural risk factors. We then included significant predictors in a 
multivariable model. Because of the sparseness of our outcome, we confirmed the robustness 
of the multivariable analysis using a logistic regression model with penalised likelihood 
estimation, which was developed for use with rare outcomes. A significance level of p<0.05 
was used in all analyses. 
2.2. Latent class models 
We then estimated latent class models to examine potential subgroups of GBM who 
inject drugs by type of drug injected in the last year. We estimated models using full 
information maximum likelihood and weakly informative, data-driven prior distributions to 
stabilise estimation. We tested these models with a successive number of classes, starting with 
two classes, until we reached an optimal solution on scaled relative entropy (roughly equivalent 
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to R2 in a linear regression). We then interpreted the latent classes by examining the conditional 
probabilities of injecting different drugs within each class (i.e., how likely those in each latent 
class were to have injected each of the six drugs). All models were implemented in Stata v 14 
(Statacorp, College Station, TX). 
3. Results 
Of the 16,464 GBM in our sample, 303 (1.81%) reported injecting in the last year. An 
additional 176 GBM (1.05%) reported ever injecting, but more than 12 months ago. In total, 
16,288 GBM (97.14%) report never injecting drugs. More than half of the sample (52.97%) 
was between the ages of 30 and 59, and nearly a quarter (24.10%) of the sample was from the 
London integrated region. More than two-thirds (67.20%) reported that their last HIV test was 
negative (see Table 1). 
3.1. Correlates with last-year injecting 
Based on bivariate regressions, GBM between the ages of 30 and 59 were most likely 
to have injected drugs and those between the ages of 16 and 19 were least likely to inject (see 
Table 1). GBM reporting injecting drug use were more likely to live in London than other 
regions of the UK. Compared to GBM who last tested negative for HIV, GBM who tested 
positive were more likely to have injected, and GBM who had never received a test result were 
less likely to have injected. GBM who did identified as gay were more likely to have injected 
than those who did not. Neither education nor full-time employment was significantly 
associated with last-year injecting. 
Sexual history in the last year was associated with last-year injecting. Compared to 
GBM who had one or more steady partners but had not engaged in cUAI, GBM with no steady 
partners or one or more steady partners with cUAI were more likely to have injected in the last 
year. Associations with non-steady partners showed a similar trend, but GBM with non-steady 
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partners and no cUAI were no more or less likely to inject than those with no non-steady 
partners. 
Multivariable models presented a similar picture, though sexual identity was no longer 
a significant correlate of last-year injecting and not all UK regions were significantly different 
from London in last-year injecting. Multivariable model results were similar with penalised 
quasi-likelihood estimation. 
3.2. Latent class models 
We tested a two-class, three-class and four-class solution and chose a three-class 
solution (see Table 2) because it had the optimal balance between fit to the data and complexity 
based on relative squared entropy. 
The first class, chemsex injecting drug use, was defined by use of mostly crystal 
methamphetamine and mephedrone, as these were the two highest conditional probabilities in 
the class. That is, this class was composed mostly of GBM who inject drugs who used either 
or both of these drugs but showed little use of other drugs. Use of ketamine in this class was 
about the same in the sample of GBM who inject drugs as a whole. In contrast, use of heroin 
was almost non-existent in this class. This class composed 88.6% of GBM reporting last-year 
injecting drug use. 
The second class, opiate injecting drug use, was characterised by low probabilities 
across all drugs, though heroin was most injected in this class and notably crystal 
methamphetamine, mephedrone and ketamine injecting were much rarer in this class than in 
the sample of GBM who inject drugs as a whole. This class composed 7.9% of GBM reporting 
last-year injecting drug use. 
Finally, the third class, eclectic injecting drug use, was characterised by high injecting 
across all drugs, but most notably across amphetamine, crystal methamphetamine, mephedrone 
and ketamine. That is, this class was composed of GBM most of whom injected all four of 
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these drugs in the last year. GHB injecting was also more than eight times as likely in this class 
as in the sample of GBM who inject drugs as a whole. Only 3.5% of GBM reporting last-year 
injecting drug use belonged to this class. 
4. Discussion 
This is the first epidemiological analysis describing subgroups of injectors among GBM 
living in the UK, and the first to describe correlates of injecting drug use in UK GBM. We 
were able to describe subgroups within the sample of GBM reporting injecting drugs in the last 
year. Most GBM who engaged in injecting either injected crystal methamphetamine, 
mephedrone or both, whereas a smaller group described engaging in generic injecting practices 
with a focus on opiates. A small but identifiable subgroup engaged in injecting across the range 
of drugs examined. As compared to the most recent evidence in injecting drug use on GBM in 
Australia (Bui et al., 2018), our study showed lower prevalence of injecting (1.81% in the last 
year in this analysis vs 4.7% in the last six months in their study) and no relationship between 
employment and injection drug use. While we did not find a significant relationship in bivariate 
models, they found that unemployment was predictive of higher prevalence of injection drug 
use. Like their study, we found that injection drug use was positively associated with middle 
age, known HIV seropositive status and more sexual partners in the recent past. Moreover, as 
compared to estimates of population prevalence of injecting in the United Kingdom at 3.0 per 
1,000 population (European Monitoring Centre for Drugs and Drug Addiction, 2017), our 
study showed a much higher prevalence. 
A key implication for design of harm reduction services is that the vast majority of 
GBM who reported injecting drug use were injecting drugs associated with chemsex, and not 
opiates, for whom most harm reduction services in the UK are designed (Bourne et al., 2015a). 
Harm reduction services for a variety of injecting behaviours, that is to say, for chemsex drugs 
in which injection use is generally related to sexual behaviour and not just for opiates, should 
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be available to all GBM. In addition, it is important to understand the small but potentially very 
high-risk group of GBM who reported eclectic injection drug use (class 3), though our data do 
not permit an understanding of safe injecting practices and contexts. 
4.1. Limitations 
We drew on a community-based sample of GBM known to be at higher sexual risk 
(Dodds et al., 2006; Prah et al., 2016). Because data collection was internet-based, we under-
represent GBM with less structured access to internet services. In addition, we only asked about 
injection of six different types of drugs. The cross-sectional nature of our data mean that 
temporality (and thus causality) cannot be established between correlates and drug use. Future 
research should seek to understand correlates of membership in different types of injection 
drug use to better inform intervention targeting. 
4.2. Conclusions 
Evidence to support an informed response to injection drug use in GBM remains scant. 
However, these analyses provide preliminary epidemiologic intelligence to support service 
design and provision to minimise the harms accruing from injecting drug use among gay men 
and other GBM. 
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Table 1. Correlates with last-year injecting in GBM. *p<0.05, **p<0.01, ***p<0.001 
 
Variable 
Distribution in 
the analysis 
sample (%) 
n/N (%) reporting 
last year injecting 
OR (95% CI) adjusted OR (95% CI) 
Age range 
16-19 7.50 3/1,254 (0.24) 0.23* (0.07, 0.72) 0.42 (0.13, 1.36) 
20-29 35.23 62/5,887 (1.05) Ref Ref 
30-59 52.97 229/8,685 (2.64) 2.54*** (1.92, 3.38) 1.56** (1.13, 2.16) 
60+ 5.30 9/885 (1.02) 0.97 (0.48, 1.95) 0.98 (0.47, 2.06) 
Highest qualification 
No secondary qualifications, O-levels, GCSE 17.66 43/2,903 (1.48) Ref   
A-levels 33.76 91/5,550 (1.64) 1.11 (0.77, 1.60)   
University degree 48.59 156/7,988 (1.95) 1.32 (0.94, 1.86)   
Employment 
Employed full-time 58.74 177/9,733 (1.82) Ref   
Not employed full-time 41.26 117/6,838 (1.71) 0.94 (0.74, 1.19)   
Where respondent lives 
London integrated region and centre 24.10 128/3,950 (3.24) Ref Ref 
North of England 23.67 51/3,880 (1.31) 0.40*** (0.29, 0.55) 0.65* (0.45, 0.93) 
Midlands and East of England 21.14 50/3,465 (1.44) 0.44*** (0.31, 0.61) 0.71 (0.49, 1.03) 
South of England 22.32 47/3,658 (1.28) 0.39*** (0.28, 0.54) 0.50*** (0.34, 0.73) 
Devolved nations 8.77 21/1,438 (1.46) 0.44*** (0.28, 0.70) 0.69 (0.41, 1.17) 
HIV testing history 
Last test negative 67.20 123/11,233 (1.09) Ref Ref 
Never received a test result 23.98 14/4,009 (0.35) 0.32*** (0.18, 0.55) 0.68 (0.38, 1.20) 
Test positive 8.82 166/1,474 (11.26) 11.46*** (9.02, 11.57) 5.54*** (4.18, 7.36) 
Sexual identity 
Gay 84.41 272/13,991 (1.94) Ref Ref 
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Other 15.59 25/2,585 (0.97) 0.49*** (0.33, 0.74) 0.71 (0.44, 1.12) 
Steady male partners for cUAI in the last year 
Steady partner(s), no cUAI 16.79 20/2,541 (0.79) Ref Ref 
No steady partner 40.89 127/6,189 (2.05) 2.64*** (1.64, 4.24) 1.29 (0.78, 2.14) 
1 steady cUAI partner 34.53 80/5,226 (1.53) 1.96** (1.20, 3.21) 1.51** (1.42, 4.53) 
2+ steady cUAI partners 7.78 58/1,178 (4.92) 6.53*** (3.91, 10.90) 2.22** (5.27, 12.67) 
Non-steady male partners for cUAI in the last year 
Non-steady partner(s), no cUAI 38.37 26/5,825 (0.45) Ref Ref 
No non-steady partners 26.86 21/4,078 (0.51) 1.15 (0.65, 2.05) 1.22 (0.67, 2.22) 
1 non-steady cUAI partner 13.10 22/1,989 (1.11) 2.49** (1.41, 4.41) 2.54** (1.42, 4.53) 
2+ non-steady cUAI partners 21.67 215/3,290 (6.53) 15.59*** (10.36, 23.48) 8.17*** (5.27, 12.67) 
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Table 2. Latent classes of injecting drug use in GBM. 
 
Drug % (n) Class 1 (%) Class 2 (%) Class 3 (%) 
Amphetamine 5.94 (18) 2.43 15.97 71.90 
Crystal meth 60.07 (182) 63.54 11.79 81.67 
Heroin 3.63 (11) 0.002 37.35 18.82 
Mephedrone 60.40 (183) 63.34 10.28 99.67 
GHB/GBL 1.98 (6) 1.21 4.20 16.43 
Ketamine 11.88 (36) 9.49 0.06 98.92 
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